Skip to main content
. Author manuscript; available in PMC: 2014 Mar 24.
Published in final edited form as: Clin Genitourin Cancer. 2012 Jun 12;10(4):232–238. doi: 10.1016/j.clgc.2012.05.001

Table 2.

Treatment Responses by Modified RECIST Criteria

Treatment Response Ridaforolimus (N = 38) Number of Patients, n (%)
Complete Response 0 (0)
Partial Response 0 (0)
Stable Disease 18 (47.4)
Progressive Disease 5 (13.2)
Unable to Evaluate 1 (2.6)
Not Assessed 14 (36.8)

Abbreviation: RECIST = Response Evaluation Criteria in Solid Tumors.